How many subsidiaries does TELA Bio, Inc. file with the SEC?

1, listed in its most recent exhibit 21. All of them are incorporated in England and Wales. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.

Is TELA Bio, Inc. financially healthy?

TELA Bio, Inc. scores 3 out of 9 on the Piotroski F-score. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of TELA Bio, Inc.?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are GEODE CAPITAL MANAGEMENT, LLC (trimming), BlackRock, Inc. (trimming), STATE STREET CORP (unchanged). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

TELA Bio, Inc. (TELA)

Nasdaq · Common Stock · Surgical & Medical Instruments & Apparatus

One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.

company in Malvern, United States

Corporate structure

1 entity across 1 jurisdiction. Read directly from the company’s own 10-K EX-21 filed 2026-03-25 — see the exhibit.

Which other public companies file entities in the same places:

England and Wales1

Subsidiaries of TELA Bio, Inc. as disclosed in its SEC filing
Entity	Jurisdiction	Note
TELA Bio, Limited	England and Wales

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

3 / 9

FAILReturn on assets positiveROA -47.7%
FAILOperating cash flow positiveOCF -28M
FAILReturn on assets improving-43.7% → -47.7%
PASSCash flow exceeds earningsOCF -28M vs NI -39M
FAILLong-term debt ratio falling47.5% → 68.4% of assets
FAILCurrent ratio improving5.01 → 4.20
FAILNo share dilution29M → 47M shares
PASSGross margin improving67.1% → 67.7%
PASSAsset turnover improving0.80× → 0.99×

Altman Z-score

-5.97distress

Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2020	$18.2M	−$28.8M	−$24.6M	61.7%	12,934,421
FY2021	$29.5M	−$33.3M	−$31.1M	63.9%	14,473,213
FY2022	$41.4M	−$44.3M	−$41.6M	65.3%	16,267,678
FY2023	$58.5M	−$46.7M	−$41.5M	68.6%	22,868,663
FY2024	$69.3M	−$37.8M	−$42.6M	67.1%	28,526,441

Ownership flow

6 institutions tracked — 1 added, 2 reduced, 1 opened a new position. Active managers added 5,500 shares while index money cut 157,134.

Institutional holders of TELA Bio, Inc. and their share-count change
Manager	Kind	Shares	Change	Value
BlackRock, Inc.	Index	374,516	−91,298	$280.9M
GEODE CAPITAL MANAGEMENT, LLC	Index	389,223	−65,836	$292.0M
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	58,100	+5,500	$43.6M

MORGAN STANLEY holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.

From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.

Identity

CIK: 0001561921
LEI: 549300I1AHR8KMMFIS52
FIGI: BBG004CH7Z50
SIC: 3841 · Surgical & Medical Instruments & Apparatus
Incorporated: DE
Headquarters: MALVERN, PA
Founded: 2012-01-01

Ownership

Institutional: 63.3%
Institutions: 50
Insiders: 7.1%

Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.

Questions about TELA Bio, Inc.

How many subsidiaries does TELA Bio, Inc. file with the SEC?: 1, listed in its most recent exhibit 21. All of them are incorporated in England and Wales. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.
Is TELA Bio, Inc. financially healthy?: TELA Bio, Inc. scores 3 out of 9 on the Piotroski F-score. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of TELA Bio, Inc.?: Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are GEODE CAPITAL MANAGEMENT, LLC (trimming), BlackRock, Inc. (trimming), STATE STREET CORP (unchanged). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

This page is one panel of the terminal

The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.

Download the terminal See pricing

Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.